Merck & Company Inc (MRK)vsSIGA Technologies Inc (SIGA)
MRK
Merck & Company Inc
$120.79
-3.46%
HEALTHCARE · Cap: $285.64B
SIGA
SIGA Technologies Inc
$4.30
-2.93%
HEALTHCARE · Cap: $314.15M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 70032% more annual revenue ($65.77B vs $93.78M). SIGA leads profitability with a 21.6% profit margin vs 13.6%. SIGA appears more attractively valued with a PEG of 3.37. SIGA earns a higher WallStSmart Score of 50/100 (C-).
MRK
Hold50
out of 100
Grade: D+
SIGA
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Margin of Safety
+75.8%
Fair Value
$27.44
Current Price
$4.30
$23.14 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Earnings expanding 1802.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 22 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Revenue declined 11.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : SIGA
The strongest argument for SIGA centers on EPS Growth, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 21.6% and operating margin at -85.2%.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : SIGA
The primary concerns for SIGA are Market Cap, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
MRK profiles as a value stock while SIGA is a declining play — different risk/reward profiles.
SIGA carries more volatility with a beta of 0.85 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 50/100). SIGA offers better value entry with a 75.8% margin of safety. Both earn "Hold" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →SIGA Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health safety and infectious disease markets in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?